XML 45 R53.htm IDEA: XBRL DOCUMENT v2.4.1.9
Commitments and Contingencies (Details) (Theravance Biopharma, USD $)
12 Months Ended
Dec. 31, 2014
sqft
Loss Contingencies  
Office space subleased 4,847thrx_AreaOfSpaceSubleased
Minimum sublease payments abstract  
2015 $ 186,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear
2016 192,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears
2017 197,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears
2018 203,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears
2019 210,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears
There after 89,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter
Total 1,077,000us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions
Lease payments guarantee
 
Loss Contingencies  
Total lease payments 33,400,000us-gaap_OperatingLeasesFutureMinimumPaymentsDue
/ us-gaap_GuaranteeObligationsByNatureAxis
= us-gaap_PropertyLeaseGuaranteeMember
/ dei_LegalEntityAxis
= thrx_TheravanceBiopharmaMember
Other long-term liabilities $ 1,300,000us-gaap_GuaranteesFairValueDisclosure
/ us-gaap_GuaranteeObligationsByNatureAxis
= us-gaap_PropertyLeaseGuaranteeMember
/ dei_LegalEntityAxis
= thrx_TheravanceBiopharmaMember